AbbVie Inc. is challenging the Trump administration’s decision to select its Botox drug for a government program that slashes ...

AbbVie (NYSE:ABBV) has filed a lawsuit against the U.S. Department of Health and Human Services over the inclusion of Botox in Medicare price negotiations. The company argues that Botox should be ...

AbbVie has sued the Department of Health and Human Services (HHS), challenging the agency’s decision to select its ...

AbbVie sues HHS over Botox Medicare pricing, challenging CMS authority under the Inflation Reduction Act and drug price negotiation rules.

In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming price cuts under the Inflation Reduction Act (IRA), AbbVie is the late | The ...

AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a plasma-derived product.

Fifteen prescription medications will be the focus of federal price negotiations that could lower prices for Medicare patients.

Add Yahoo as a preferred source to see more of our stories on Google. President Donald Trump and the Centers for Medicare & Medicaid Services (CMS) recently announced the 15 drugs whose prices they ...

The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations. The list includes Botox and the GLP-1 drug Trulicity. The negotiations stem from ...

By Jonathan Stempel Feb 11 (Reuters) - AbbVie sued the U.S. Department of Health and Human Services on Wednesday, challenging ...

Botox vs fillers compared. Understand cosmetic injectables, treatment differences, and what to expect from today's anti aging ...